# EDGAR Filing Document

**Accession Number:** 0001920092
**File Stem:** 0000000000-25-007162
**Filing Date:** 2025-7
**Character Count:** 2360
**Document Hash:** 9fda6ba3b7f43ff564360391cee3f826
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-25-007162.hdr.sgml**: 20250929

**ACCESSION NUMBER**: 0000000000-25-007162

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20250708

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Gelteq Ltd
- **CENTRAL INDEX KEY:** 0001920092
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** C3
- **FISCAL YEAR END:** 0630

**FILING VALUES:**
- **FORM TYPE:** UPLOAD
- **SEC FILE NUMBER:** 333-288442

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** LEVEL 4
- **STREET 2:** 100 ALBERT ROAD
- **CITY:** SOUTH MELBOURNE VIC
- **PROVINCE COUNTRY:** C3
- **BUSINESS PHONE:** 61390873990

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** LEVEL 4
- **STREET 2:** 100 ALBERT ROAD
- **CITY:** SOUTH MELBOURNE VIC
- **PROVINCE COUNTRY:** C3

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Gelteq Pty Ltd.
- **DATE OF NAME CHANGE:** 20220328
**PUBLIC REFERENCE ACCESSION NUMBER**: 0001213900-25-059880

## Text-Extract

```

                                                           July 8, 2025

Nathan Givoni
Chief Executive Officer and Director
Gelteq Limited
Level 4
100 Albert Road
South Melbourne VIC, 3025
Australia

       Re: Gelteq Limited
           Registration Statement on Form F-1
           Filed July 1, 2025
           File No. 333-288442
Dear Nathan Givoni:

       This is to advise you that we have not reviewed and will not review your
registration
statement.

        Please refer to Rules 460 and 461 regarding requests for acceleration.
We remind you
that the company and its management are responsible for the accuracy and
adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action
by the staff.

       Please contact Daniel Crawford at 202-551-7767 with any questions.

                                                           Sincerely,

                                                           Division of
Corporation Finance
                                                           Office of Life
Sciences
cc:   Richard Anslow, Esq.

```

### Attached PDF Documents

**Attachment 1:** `filename1`

_No text found in this document._